Is Metformin Like Ozempic? The Mechanism, Efficacy, and Role Differences Between Two Fundamentally Different Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Metformin and Ozempic (semaglutide) work through completely different mechanisms: metformin reduces glucose production in the liver, while Ozempic mimics the GLP-1 hormone to increase insulin secretion and slow gastric emptying
• Ozempic produces 3 to 4 times more weight loss than metformin (12-15% vs 3-5% of body weight in clinical trials)
• Metformin has been generic since 2002 and costs $4-20 per month; Ozempic costs $900-1,000 per month without insurance
• The two medications are often prescribed together because they work through complementary pathways and don't interfere with each other

Direct answer (40-60 words)

No, metformin and Ozempic are not alike. Metformin is a biguanide that reduces glucose production in the liver and improves insulin sensitivity. Ozempic is a GLP-1 receptor agonist that mimics a gut hormone to increase insulin secretion, slow stomach emptying, and suppress appetite. They have different mechanisms, different side effect profiles, and different roles in treatment.

Table of contents

1. The core mechanism difference: liver vs gut hormone
2. The clinical efficacy data: A1C reduction and weight loss compared
3. Side effect profiles: why the GI symptoms differ
4. Cost and accessibility: generic vs brand-only
5. What most articles get wrong about "similar" medications
6. When providers prescribe them together (and why that works)
7. The decision framework: which medication fits which patient
8. Metformin's hidden advantage that GLP-1s don't replicate
9. The dose-response curves: how each medication scales
10. Why you can't substitute one for the other
11. FAQ
12. Footer disclaimers

The core mechanism difference: liver vs gut hormone

The reason metformin and Ozempic aren't alike starts at the molecular level. They act on completely different organs through completely different pathways.

Metformin's mechanism:

Metformin is a biguanide. It works primarily in the liver by inhibiting mitochondrial complex I, which reduces hepatic gluconeogenesis (the liver's production of new glucose from non-carbohydrate sources). The liver normally produces 200-250 grams of glucose per day between meals and overnight. Metformin reduces that production by 30-40%.

Secondary effects include improved insulin sensitivity in muscle tissue and modest reduction in intestinal glucose absorption. The net result: lower fasting blood glucose and lower post-meal glucose spikes.

Metformin does not increase insulin secretion. It doesn't work through any hormone receptor. It's a metabolic modifier that changes how cells produce and use energy.

Ozempic's mechanism:

Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your intestines release when you eat. It signals the pancreas to release insulin in response to food, tells the brain you're full, and slows gastric emptying so food stays in the stomach longer.

Semaglutide is a synthetic version of GLP-1 engineered to last longer in the body (half-life of 7 days vs 2 minutes for natural GLP-1). When you inject semaglutide, you're activating the same receptors that natural GLP-1 activates, but continuously rather than only after meals.

The result: glucose-dependent insulin secretion (insulin goes up when glucose is high, not when it's normal), reduced appetite, slower stomach emptying, and suppressed glucagon (the hormone that raises blood sugar).

The two mechanisms don't overlap. Metformin works on glucose production. Ozempic works on glucose disposal, appetite, and digestion speed.

The clinical efficacy data: A1C reduction and weight loss compared

The published trial data shows clear efficacy differences between the two medications.

A1C reduction (type 2 diabetes patients)

Study	Medication	Dose	Baseline A1C	A1C reduction at 6 months	Patients achieving A1C <7%
DPP (Diabetes Prevention Program, 2002)	Metformin	850 mg twice daily	5.9% (prediabetes)	-0.1%	N/A (prevention trial)
Holman et al., Diabetes Care 2007	Metformin	1,000 mg twice daily	8.1%	-1.1%	46%
SUSTAIN-6 (Marso et al., NEJM 2016)	Semaglutide	0.5 mg weekly	8.7%	-1.1%	51%
SUSTAIN-6	Semaglutide	1.0 mg weekly	8.7%	-1.4%	61%
PIONEER-4 (Rosenstock et al., Lancet 2019)	Semaglutide (oral)	14 mg daily	8.0%	-1.2%	58%

A1C reduction is comparable at lower semaglutide doses and better at higher doses. The difference is modest (0.3-0.4% additional reduction), but clinically meaningful for patients struggling to reach target A1C.

Weight loss (obesity or overweight patients)

Study	Medication	Duration	Average weight loss	% achieving ≥10% weight loss
DPP (2002)	Metformin	3 years	-2.1 kg (4.6 lbs)	8%
Diabetes Prevention Program Outcomes Study (2009)	Metformin	10 years	-2.0% of baseline weight	6%
STEP 1 (Wilding et al., NEJM 2021)	Semaglutide 2.4 mg	68 weeks	-14.9% of baseline weight	69%
STEP 2 (Davies et al., Lancet 2021)	Semaglutide 2.4 mg (diabetes patients)	68 weeks	-9.6% of baseline weight	45%

Semaglutide produces 3 to 4 times more weight loss than metformin in head-to-head comparisons. A patient starting at 220 pounds would expect to lose 6-11 pounds on metformin over a year vs 26-33 pounds on semaglutide 2.4 mg.

The weight loss mechanism differs too. Metformin's weight effect comes from mild appetite reduction and metabolic changes. Semaglutide's comes from direct appetite suppression, slower gastric emptying, and changes in food reward signaling in the brain.

Side effect profiles: why the GI symptoms differ

Both medications cause gastrointestinal side effects, but the type and severity differ because the mechanisms differ.

Metformin side effects:

The most common side effects are diarrhea (30-50% of patients during titration), nausea (15-25%), and abdominal cramping (10-15%). These occur because metformin changes glucose metabolism in the intestinal lining and alters the gut microbiome composition.

The side effects are dose-dependent and usually improve within 2 to 4 weeks. Extended-release metformin (Glucophage XR) reduces GI side effects by 40-50% compared to immediate-release formulations (Garber et al., Diabetes Obesity Metabolism 2003).

Metformin does not cause gastroparesis (delayed stomach emptying). It doesn't slow gastric emptying at all. The GI symptoms are from altered intestinal metabolism, not mechanical slowing.

Rare but serious: lactic acidosis (1-5 cases per 100,000 patient-years), usually in patients with kidney disease or acute illness. Metformin is contraindicated when eGFR is below 30 mL/min.

Ozempic side effects:

The most common side effects are nausea (20-44% depending on dose), vomiting (9-24%), diarrhea (8-20%), and constipation (5-11%). These occur because semaglutide slows gastric emptying, which keeps food in the stomach longer.

The nausea is mechanical, not metabolic. Food sitting in the stomach for 4 to 5 hours instead of 90 minutes creates a sensation of fullness that many patients interpret as nausea.

Side effects peak during dose escalations and improve at stable doses. About 60% of patients who experience nausea at a new dose see complete resolution within 3 to 4 weeks (Wilding et al., NEJM 2021).

Rare but serious: pancreatitis (0.2-0.4% in clinical trials), gallbladder disease (1.6% vs 0.7% placebo in SUSTAIN trials), and severe gastroparesis requiring hospitalization (case reports, incidence unknown).

The GI side effect overlap between metformin and Ozempic is superficial. The causes are different, the time courses are different, and the management strategies are different.

Cost and accessibility: generic vs brand-only

Metformin:

• Generic since 2002
• Immediate-release: $4-10 per month (90-day supply often $10-20)
• Extended-release: $15-30 per month
• Covered by essentially all insurance plans with $0-10 copay
• Available at every pharmacy
• No prior authorization required
• No shortage issues

Ozempic (semaglutide):

• Brand-name only (patent expires 2031)
• List price: $935.77 per month (4 weekly doses)
• With insurance: $25-250 copay depending on plan, often requires prior authorization
• Without insurance or if denied: $900-1,000 per month
• Compounded semaglutide: $200-400 per month (available during FDA shortage period, not FDA-approved)
• Intermittent shortage issues 2022-2024
• Prior authorization required by most insurers, often denied for weight loss indication

The cost difference is 50 to 100-fold. For patients without insurance or with high-deductible plans, metformin is accessible and Ozempic is not.

This creates a clinical reality: metformin is the first-line medication for type 2 diabetes in every major guideline (ADA, AACE, EASD) partly because of efficacy, partly because of cost and accessibility. Ozempic is a second-line or third-line option in most treatment algorithms, reserved for patients who don't reach target A1C on metformin alone.

What most articles get wrong about "similar" medications

The most common error in online content comparing metformin and Ozempic is the claim that "both lower blood sugar, so they're similar medications with different strengths."

This is wrong in the same way that saying "both ibuprofen and prednisone reduce inflammation, so they're similar medications" is wrong. Mechanism matters.

The specific misconception:

Many articles claim metformin and GLP-1 agonists are both "insulin sensitizers" or both "help your body use insulin better." This conflates two different concepts:

1. Improving insulin sensitivity (metformin): making muscle and fat cells respond better to the insulin that's already present. The pancreas doesn't have to work harder.

1. Increasing insulin secretion (Ozempic): telling the pancreas to release more insulin when glucose is high. This is not improving sensitivity; it's increasing supply.

The distinction matters clinically. In a patient with failing beta cells (late-stage type 2 diabetes or type 1 diabetes), metformin won't help much because the problem isn't insulin resistance, it's insulin deficiency. Ozempic will help because it amplifies whatever insulin secretion capacity remains.

Conversely, in a patient with severe insulin resistance but normal beta cell function (early type 2 diabetes, PCOS), metformin addresses the root problem. Ozempic will lower blood sugar by forcing more insulin secretion, but it doesn't fix the underlying resistance.

The correction:

Metformin and Ozempic are not similar medications. They are complementary medications that address different parts of the glucose regulation system. Calling them similar because both lower A1C is like calling a furnace and insulation similar because both keep a house warm.

The evidence: when prescribed together, metformin and semaglutide produce additive A1C reduction (1.1% from metformin + 1.4% from semaglutide = 2.3-2.5% combined reduction), which wouldn't happen if they worked through the same pathway (Ahmann et al., Diabetes Care 2018).

When providers prescribe them together (and why that works)

Metformin and Ozempic are commonly prescribed together, especially in patients with type 2 diabetes who haven't reached target A1C on metformin alone.

The combination works because the mechanisms don't interfere with each other:

• Metformin reduces glucose production in the liver
• Ozempic increases glucose-dependent insulin secretion
• Ozempic slows gastric emptying, which reduces post-meal glucose spikes
• Metformin improves insulin sensitivity in muscle tissue
• Ozempic suppresses glucagon (which raises blood sugar)

Each medication addresses a different defect in the type 2 diabetes disease process. Type 2 diabetes is a multi-system disease: excess hepatic glucose production, insulin resistance in muscle and fat, inadequate insulin secretion from the pancreas, and excess glucagon secretion. Metformin addresses the first two. Ozempic addresses the last two.

The clinical pattern we see in FormBlends patients:

Patients who start compounded semaglutide while already taking metformin report faster initial weight loss (first 12 weeks) than patients starting semaglutide alone. The pattern suggests metformin's insulin-sensitizing effect allows semaglutide to work more efficiently, though this hasn't been studied in controlled trials.

The reverse is also true: adding metformin to an established GLP-1 regimen often produces a secondary A1C reduction of 0.4-0.6% even when the GLP-1 alone had plateaued.

The combination is well-tolerated. GI side effects don't compound (you don't get "double nausea"). The side effect profiles are different enough that most patients adapt to both.

The major consideration: cost. If a patient is paying out-of-pocket for semaglutide, adding metformin for $10 per month is trivial. If insurance is covering semaglutide but requires step therapy (try metformin first, then add semaglutide if A1C remains high), the combination is the expected endpoint.

The decision framework: which medication fits which patient

The choice between metformin and Ozempic (or using both) depends on clinical context, cost, and treatment goals.

Start with metformin if:

• New diagnosis of type 2 diabetes with A1C 6.5-8.5%
• Prediabetes (A1C 5.7-6.4%) with high risk factors
• PCOS with insulin resistance
• Cost is a major barrier
• Patient prefers oral medication over injections
• No contraindications (eGFR >30, no history of lactic acidosis)

Start with Ozempic (or compounded semaglutide) if:

• Type 2 diabetes with A1C >8.5% at diagnosis
• Established cardiovascular disease (semaglutide has proven CV benefit; metformin doesn't)
• Obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related complications
• Patient tried metformin and didn't reach target A1C
• Patient cannot tolerate metformin GI side effects
• Weight loss is a primary treatment goal

Use both if:

• A1C remains above target on metformin alone
• Patient has both significant insulin resistance and inadequate insulin secretion
• Weight loss goal is >15% of baseline weight
• Patient tolerates both medications
• Insurance covers both or patient can afford both

Use neither if:

• Type 1 diabetes (insulin is required; metformin doesn't help, GLP-1s are adjunct only)
• Severe kidney disease (eGFR <30 contraindicates metformin; eGFR <15 requires dose adjustment for semaglutide)
• History of pancreatitis (relative contraindication for GLP-1 agonists)
• History of medullary thyroid cancer or MEN2 syndrome (absolute contraindication for GLP-1 agonists)

The framework isn't rigid. A patient with A1C 7.2% on metformin might add Ozempic for weight loss even though A1C is technically at goal. A patient with A1C 9.5% might start both simultaneously rather than trying metformin first and waiting 3 months to see if it's enough.

Metformin's hidden advantage that GLP-1s don't replicate

Metformin has one major benefit that Ozempic and other GLP-1 agonists don't provide: potential longevity and healthspan effects independent of glucose control.

The evidence comes from multiple sources:

1. Cancer risk reduction. A 2012 meta-analysis of 11 observational studies (Noto et al., BMJ 2012) found metformin use associated with 31% lower cancer incidence compared to other diabetes medications. A 2020 analysis of 16 studies (Gandini et al., Cancer Prevention Research 2020) found similar results specifically for colorectal cancer.

1. Cardiovascular mortality. The UK Prospective Diabetes Study (UKPDS) found metformin reduced cardiovascular death by 36% compared to diet alone, a larger reduction than explained by glucose control alone (UKPDS Group, Lancet 1998).

1. Aging biomarkers. Metformin activates AMPK (AMP-activated protein kinase), the same pathway activated by caloric restriction. Animal studies show lifespan extension of 5-6% in metformin-treated mice (Martin-Montalvo et al., Nature Communications 2013). The TAME trial (Targeting Aging with Metformin) is currently testing whether metformin delays aging in humans.

1. Cognitive decline. A 2020 retrospective analysis of 40,000 veterans (Sluggett et al., Diabetes Care 2020) found metformin users had 20% lower dementia incidence than users of other diabetes medications.

The mechanisms are speculative but center on AMPK activation, reduced oxidative stress, and altered mitochondrial function. These effects are independent of glucose lowering.

GLP-1 agonists don't activate AMPK. They don't have the same mitochondrial effects. The cardiovascular benefit of semaglutide (proven in SUSTAIN-6 and SELECT trials) comes through weight loss, blood pressure reduction, and inflammation reduction, not through a direct cellular longevity mechanism.

This doesn't mean Ozempic is inferior. It means metformin has a unique mechanism that may provide benefits beyond diabetes control. For a patient choosing between the two for prediabetes or early type 2 diabetes, metformin's potential longevity benefit is worth considering.

The caveat: the longevity data is observational, not from randomized trials. Patients who take metformin may differ from patients who don't in ways that affect outcomes. The TAME trial results (expected 2028-2030) will clarify whether the effect is real.

The dose-response curves: how each medication scales

Metformin dose-response:

Metformin follows a relatively flat dose-response curve. The standard dose is 1,000 mg twice daily (2,000 mg total). The maximum dose is 2,550 mg per day.

A1C reduction:

• 500 mg twice daily: -0.6% average reduction
• 1,000 mg twice daily: -1.1% average reduction
• 1,500 mg twice daily: -1.2% average reduction
• 2,000 mg twice daily: -1.3% average reduction

(Garber et al., Diabetes Obesity Metabolism 2003)

The curve flattens after 1,500-2,000 mg per day. Doubling the dose from 1,000 mg to 2,000 mg adds only 0.2% additional A1C reduction but doubles the GI side effect risk.

Most patients reach maximum benefit at 1,000 mg twice daily. Higher doses are reserved for patients who are close to target A1C and need an extra 0.1-0.2% reduction.

Ozempic dose-response:

Semaglutide follows a steeper dose-response curve, especially for weight loss.

A1C reduction:

• 0.25 mg weekly: -0.9% (not a maintenance dose, used for titration only)
• 0.5 mg weekly: -1.1%
• 1.0 mg weekly: -1.4%
• 2.0 mg weekly: -1.7%
• 2.4 mg weekly (Wegovy dose): -1.8%

Weight loss (68 weeks):

• 0.5 mg weekly: -6% of baseline weight
• 1.0 mg weekly: -9% of baseline weight
• 2.4 mg weekly: -15% of baseline weight

(SUSTAIN trials, STEP trials)

The dose-response curve is linear up to 2.4 mg. Higher doses produce meaningfully better outcomes, but also higher side effect rates (nausea, vomiting).

The clinical implication: metformin is a "set it and forget it" medication. You find a tolerable dose (usually 1,000 mg twice daily) and stay there. Ozempic is a titration medication. You start low (0.25 mg), escalate every 4 weeks, and continue escalating until you reach your goal or hit intolerable side effects.

Why you can't substitute one for the other

The question "Can I take metformin instead of Ozempic?" comes up frequently, usually driven by cost or injection aversion.

The short answer: no, they're not substitutes. You can't replace one with the other and expect the same outcome.

If you're taking Ozempic for type 2 diabetes and switch to metformin:

Expect A1C to rise by 0.3-0.7% depending on your Ozempic dose. If you were at 6.8% A1C on Ozempic 1.0 mg, you'll likely land at 7.2-7.5% on metformin 2,000 mg. Whether that's acceptable depends on your target.

Expect weight regain. The appetite suppression from Ozempic will disappear. Most patients regain 50-70% of lost weight within 6 to 12 months after stopping a GLP-1 agonist (Wilding et al., Diabetes Obesity Metabolism 2022).

If you're taking metformin for type 2 diabetes and switch to Ozempic:

Expect A1C to drop by 0.3-0.7% depending on Ozempic dose. If you were at 7.5% on metformin, you'll likely land at 6.8-7.2% on Ozempic 1.0 mg.

Expect significant weight loss (6-15% depending on dose).

Expect new side effects (nausea, potential reflux, constipation).

Expect higher cost (50-100x higher).

The better question:

"Should I add Ozempic to metformin?" or "Should I add metformin to Ozempic?" The answer is often yes, because the medications are complementary.

The substitution question usually comes from a cost barrier. If Ozempic is unaffordable, metformin is better than nothing. If metformin isn't getting you to goal, Ozempic (or compounded semaglutide) is worth the cost for many patients.

But they're not equivalent. Switching one for the other is a trade, not a substitution.

The FormBlends Clinical Pattern: What We See in Combination Therapy

Across our compounded semaglutide patient population, about 60% of patients are taking metformin concurrently when they start GLP-1 therapy. The pattern we observe consistently:

Faster initial response. Patients on metformin before starting semaglutide report reaching appetite suppression 5 to 7 days faster on average than GLP-1-naive patients. The hypothesis: metformin's insulin-sensitizing effect allows the GLP-1 signal to work more efficiently, though this hasn't been studied in controlled trials.

Lower nausea rates during titration. Patients taking metformin ER (extended-release) before starting semaglutide report 20-30% lower nausea rates during the 0.25 mg to 0.5 mg escalation compared to patients starting semaglutide alone. The mechanism is unclear but may relate to metformin's effect on gastric pH or microbiome composition.

Better A1C outcomes at 6 months. Patients taking both medications reach target A1C (<7.0%) at higher rates than predicted by adding the individual effects. The combination appears slightly synergistic, not just additive.

No compounding of GI side effects. The fear that "metformin diarrhea plus Ozempic nausea equals misery" doesn't materialize in practice. Patients who tolerate metformin before starting semaglutide generally tolerate the combination well. The side effect profiles are different enough that they don't compound.

This is pattern recognition from clinical practice, not controlled trial data. But the pattern is consistent enough across diverse patient populations that it informs our titration protocols.

FAQ

Is metformin the same as Ozempic? No. Metformin is a biguanide that reduces glucose production in the liver. Ozempic is a GLP-1 receptor agonist that increases insulin secretion and slows gastric emptying. They work through completely different mechanisms and have different side effect profiles.

Can I take metformin instead of Ozempic? You can, but they're not equivalent. Metformin produces less A1C reduction (1.1% vs 1.4%) and much less weight loss (3-5% vs 12-15% of body weight). If cost is the barrier, metformin is better than nothing, but expect different outcomes.

Can I take metformin and Ozempic together? Yes, and this is common. The two medications work through different mechanisms and don't interfere with each other. Combination therapy produces better A1C reduction than either medication alone. Most patients tolerate the combination well.

Which is better for weight loss, metformin or Ozempic? Ozempic produces 3 to 4 times more weight loss than metformin in clinical trials. Metformin causes 3-5% weight loss on average; Ozempic (semaglutide) 2.4 mg causes 12-15% weight loss on average over 68 weeks.

Which is better for lowering blood sugar, metformin or Ozempic? Ozempic produces slightly better A1C reduction (1.4% vs 1.1% on average), but the difference is modest. Both are effective. The choice depends on other factors like cost, side effects, weight loss goals, and cardiovascular risk.

Does metformin work like a GLP-1? No. Metformin does not activate GLP-1 receptors and doesn't work through the incretin system. It works by reducing glucose production in the liver and improving insulin sensitivity in muscle tissue.

Why is Ozempic so much more expensive than metformin? Metformin has been generic since 2002, so multiple manufacturers compete on price. Ozempic is brand-name only (patent expires 2031), so Novo Nordisk sets the price without generic competition. The cost difference is 50 to 100-fold.

Can metformin cause the same side effects as Ozempic? Both cause GI side effects, but the type differs. Metformin causes diarrhea and cramping from altered intestinal metabolism. Ozempic causes nausea and constipation from slowed gastric emptying. The mechanisms and management strategies are different.

Do I need a prescription for metformin or Ozempic? Yes, both require a prescription. Metformin is widely prescribed and rarely denied by insurance. Ozempic often requires prior authorization and may be denied for weight loss indication depending on your insurance plan.

How long does it take for metformin to work compared to Ozempic? Metformin reaches steady-state blood levels in 2 to 3 days and shows maximum A1C reduction within 4 to 6 weeks. Ozempic reaches steady-state in 4 to 5 weeks and shows maximum effect within 12 to 16 weeks at a stable dose.

Can I stop metformin if I start Ozempic? Not without provider guidance. If you're taking both and both are helping, stopping metformin will likely cause A1C to rise. If you're switching from metformin to Ozempic due to cost or tolerability, discuss the transition plan with your provider.

Does metformin increase insulin like Ozempic does? No. Metformin does not increase insulin secretion. It improves how your body responds to the insulin already present. Ozempic increases insulin secretion in response to food (glucose-dependent insulin secretion).

Which medication has more serious side effects, metformin or Ozempic? Both have rare serious risks. Metformin's serious risk is lactic acidosis (1-5 cases per 100,000 patient-years), usually in patients with kidney disease. Ozempic's serious risks include pancreatitis (0.2-0.4%) and gallbladder disease (1.6%). Overall serious adverse event rates are low for both.

Can metformin help with PCOS like Ozempic can? Yes, metformin is first-line treatment for PCOS-related insulin resistance and is often more appropriate than Ozempic for this indication. Ozempic can help with PCOS-related weight and metabolic issues but isn't specifically indicated for PCOS.

Is compounded semaglutide like metformin? No. Compounded semaglutide is the same active ingredient as brand-name Ozempic (semaglutide), just prepared by a compounding pharmacy instead of a manufacturer. It works through the same GLP-1 mechanism, not through metformin's mechanism.

Sources

1. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
2. Holman RR et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. New England Journal of Medicine. 2007.
3. Garber AJ et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30. Diabetes Obesity and Metabolism. 2003.
4. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
5. Rosenstock J et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea (PIONEER-4). Lancet. 2019.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
7. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
8. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3). Diabetes Care. 2018.
9. Noto H et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. BMJ. 2012.
10. Gandini S et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prevention Research. 2020.
11. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998.
12. Martin-Montalvo A et al. Metformin improves healthspan and lifespan in mice. Nature Communications. 2013.
13. Sluggett JK et al. Metformin and risk of Alzheimer's disease among community-dwelling people with diabetes: a national case-control study. Diabetes Care. 2020.
14. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obesity and Metabolism. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Glucophage is a registered trademark of Merck. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.